← Back to Screener
Artelo Biosciences, Inc. Common Stock (ARTL)
Price$1.38
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-82.67%
Price vs S&P 500 (4W)-50.13%
VGM Score17.62
Market Capitalization$4.81M
All Metrics
Book Value / Share (Quarterly)$9.91
P/TBV (Annual)4.18x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-12.43
Price vs S&P 500 (YTD)-71.95%
EPS (TTM)$-38.91
10-Day Avg Trading Volume5.01M
EPS Excl Extra (TTM)$-38.91
EPS (Annual)$-37.55
ROI (Annual)-343.93%
Cash / Share (Quarterly)$15.26
ROA (Last FY)-459.80%
EBITD / Share (TTM)$-27.58
ROE (5Y Avg)-131.38%
Cash Flow / Share (Annual)$-13.03
P/B Ratio0.72x
P/B Ratio (Quarterly)0.90x
Net Income / Employee (Annual)$-1,839,900
Net Interest Coverage (TTM)-49.51x
ROA (TTM)-224.95%
EPS Incl Extra (Annual)$-37.55
Current Ratio (Annual)0.17x
Quick Ratio (Quarterly)1.76x
3-Month Avg Trading Volume3.04M
52-Week Price Return-92.78%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.88
52-Week High$85.80
EPS Excl Extra (Annual)$-37.55
Tangible BV CAGR (5Y)-14.97%
26-Week Price Return-71.29%
Quick Ratio (Annual)0.15x
13-Week Price Return-60.28%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.79x
Enterprise Value$-4.80M
Book Value / Share Growth (5Y)5.92%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.89
3-Month Return Std Dev500.19%
Net Income / Employee (TTM)$-1,923,600
ROE (Last FY)-343.93%
Net Interest Coverage (Annual)-24.36x
EPS Basic Excl Extra (Annual)$-37.55
Total Debt / Equity (Quarterly)0.10x
EPS Incl Extra (TTM)$-38.91
ROI (TTM)-40.34%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.49
Price vs S&P 500 (52W)-119.82%
Year-to-Date Return-60.93%
5-Day Price Return2.14%
EPS Normalized (Annual)$-37.55
ROA (5Y Avg)-169.68%
Month-to-Date Return2.14%
Cash Flow / Share (TTM)$-3.33
EBITD / Share (Annual)$-36.62
ROI (5Y Avg)-131.38%
EPS Basic Excl Extra (TTM)$-38.91
P/TBV (Quarterly)1.29x
P/B Ratio (Annual)1.20x
Book Value / Share (Annual)$15.67
Price vs S&P 500 (13W)-70.78%
Beta-0.17x
Revenue / Share (TTM)$0.00
ROE (TTM)-44.33%
52-Week Low$1.19
mGradeF
vgmGradeF
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ARTLArtelo Biosciences, Inc. Common Stock | — | — | F | $1.38 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Artelo Biosciences is a clinical-stage biopharmaceutical company developing therapies targeting the endocannabinoid system, a lipid signaling pathway involved in various diseases. The company is advancing a proprietary pipeline of cannabinoid-based therapeutics derived from cannabis plants, synthetic sources, and novel chemical entities. Its flagship program is a patent-protected cannabinoid combination treatment for rare and orphan diseases.